Stuck in the middle
Article Abstract:
MediciNova, the first foreign-based biotechnology company to list its shares in Japan, is caught up in bureaucratic problems, with rules on trading of shares of foreign firms resulting in a steep fall in the share value. A step-by-step approach is recommended in Japanese systems, and other foreign biotech companies that might list on a Japanese stock market are waiting to be better prepared before they choose Japan as a base for raising money.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Anaemic outlook for Amgen
Article Abstract:
The article describes the problems faced by Amgen, a biotechnology company in California, U.S. The problem relates to the anti-anemia drugs produced and manufactured by Amgen.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Stem-cell brothers divide. Where now for stem-cell cloners? . Victims hit out at university over handling of harassment cases
- Abstracts: Swooping for biotech. Meeting in the middle. No longer the upstart
- Abstracts: Getting the right mix. Scientists attack Bush over intelligent design. Special report
- Abstracts: Among the best. Indian voices. Scientists unite in bid to drive policy
- Abstracts: Pumping up the volume. Designs on Europa unfurl. A measure of happiness